Systems, assemblies, and methods for treating a bronchial tree
Systems, assemblies, and methods to treat pulmonary diseases are used to decrease nervous system input to distal regions of the bronchial tree within the lungs. Treatment systems damage nerve tissue to temporarily or permanently decrease nervous system input. The treatment systems are capable of heating nerve tissue, cooling the nerve tissue, delivering a flowable substance that cause trauma to the nerve tissue, puncturing the nerve tissue, tearing the nerve tissue, cutting the nerve tissue, applying pressure to the nerve tissue, applying ultrasound to the nerve tissue, applying ionizing radiation to the nerve tissue, disrupting cell membranes of nerve tissue with electrical energy, or delivering long acting nerve blocking chemicals to the nerve tissue.
1. A method of treating at least partial obstruction of an airway caused by excessive intraluminal mucus, mucous glands hypertrophy, or both, the method comprising:
damaging nerve tissue via ablation at a first location along the airway so as to attenuate transmission of signals to and/or from mucous producing cells at a second location along the airway so as to reduce a production of mucous from the mucous producing cells.
2. The method of claim 1 , wherein damaging nerve tissue comprises damaging efferent nerve tissue to inhibit signals from being transmitted from the brain to airway to mucous producing cells.
3. The method of claim 1 , wherein damaging nerve tissue disrupts a baseline level of mucous secretion.
4. The method of claim 1 , wherein damaging nerve tissue attenuates transmission of signals traveling along vagus nerves that cause mucus production.
5. The method of claim 1 , wherein attenuation of the transmission of signals comprises hindering, limiting, blocking, and/or interrupting transmission of signals.
6. The method of claim 1 , wherein attenuation of the transmission of signals comprises decreasing signal amplitude, weakening transmission of signals, or both.
7. The method of claim 1 , wherein the method decreases a sufficient amount of mucus production to cause substantial decrease in coughing and/or airflow resistance.
8. The method of claim 1 , wherein the method further comprises, after damaging nerve tissue:
providing a questionnaire or test to assess a subject's response to treatment by assessing a subject's mucous secretion and comparing the assessment to an assessment of the subject's mucous secretion before damaging the nerve tissue.
9. The method of claim 1 , further comprising:
determining whether a patient is a candidate for damaging nerve tissue by measuring mucous secretion.
10. The method of claim 1 , wherein damaging nerve tissue comprises:
outputting energy from an activatable element of an intraluminal device positioned in the airway to heat and ablate the nerve tissue along an airway wall of the airway at the first location; and
cooling a portion of the intraluminal device to cool an inner portion of the airway wall while outputting the energy to inhibit damage to the inner portion of the airway wall while the nerve tissue is ablated.
11. The method of claim 1 , wherein damaging nerve tissue comprises:
delivering energy from an ablation element of an intraluminal device positioned in the airway lumen to destroy the nerve tissue along a wall of the airway lumen while avoiding injury to airway tissue distal the damaged nerve tissue.
12. The method of claim 1 , wherein the nerve tissue is positioned between the trachea and a lung of the subject.
13. The method of claim 1 , wherein damaging nerve tissue includes ablating nerve tissue of a nerve trunk along a right main bronchus, a left main bronchus, or both.
14. The method of claim 1 , wherein damaging nerve tissue comprises:
introducing an intraluminal device into the airway lumen via a trachea of a subject;
positioning the intraluminal device proximate the nerve tissue to be damaged; and
delivering energy to the nerve tissue to damage the nerve tissue, wherein the intraluminal device is positioned proximate the nerve tissue such that only the portion of a wall of the airway lumen immediately adjacent to the nerve tissue is treated.
15. The method of claim 1 , wherein the mucous producing cells define a mucous gland in the stroma of the airway wall at the second location.
16. The method of claim 1 , wherein the mucous producing cells are located in an epithelium of the airway wall at the second location.
17. A method of treating at least partial obstruction of an airway lumen caused by excessive intraluminal mucus, mucous glands hypertrophy, or both, the method comprising:
damaging nerve tissue via ablation at a first location along an airway wall of the airway lumen so as to attenuate transmission of signals to and/or from mucous producing cells so as to reduce a production of mucous from the mucous producing cells.
18. The method of claim 17 , wherein the nerve tissue is positioned between the trachea and a lung of the subject.
19. The method of claim 17 , wherein damaging nerve tissue includes ablating nerve tissue of a nerve trunk along a right main bronchus, a left main bronchus, or both.
20. The method of claim 17 , wherein the mucous producing cells define a mucous gland in the airway wall.
21. The method of claim 17 , wherein the mucous producing cells are located in an epithelium of the airway wall.
22. The method of claim 17 , wherein damaging nerve tissue comprises:
introducing an intraluminal device into the airway lumen via a trachea of a subject;
positioning the intraluminal device proximate the nerve tissue to be damaged; and
delivering energy to the nerve tissue to damage the nerve tissue, wherein the intraluminal device is positioned proximate the nerve tissue such that only the nerve tissue and a portion of the airway wall of the airway lumen immediately adjacent to the nerve tissue is treated.
23. A method of determining treatment efficacy, the method comprising:
determining, in a subject, a baseline level of mucous secretion;
providing an airway treatment to the subject by damaging nerve tissue via ablation at a first location along the airway so as to attenuate transmission of signals to and/or from mucous producing cells at a second location along the airway so as to reduce a production of mucous from the mucous producing cells; and
after damaging nerve tissue, assessing, in the subject, a level of mucous secretion to determine the treatment efficacy.
24. The method of claim 23 , wherein assessing a level of mucous secretion comprises providing questionnaires and/or tests to the subject to compare the level of mucous secretion to the baseline level to determine the treatment efficacy.
25. The method of claim 23 , wherein the level of mucous section is compared to the baseline level by comparing a level of coughing and/or airflow resistance before and after treatment.
26. The method of claim 23 , wherein providing an airway treatment to the subject comprises:
introducing an intraluminal device into a lumen of the airway via a trachea of the subject;
positioning the intraluminal device proximate the nerve tissue to be damaged; and
delivering energy to the nerve tissue to damage the nerve tissue, wherein the intraluminal device is positioned proximate the nerve tissue such that only the nerve tissue and a portion of a wall of the airway lumen immediately adjacent to the nerve tissue is treated.